

Contents

<i>M. Pfreundschuh, H. Shiku, T. Takahashi, R. Ueda, J. Ransohoff, H. F. Oettgen, and L. J. Old:</i> Tumor-Specific Antigens	1
<i>L. Olsson:</i> Autoreactive Cells as Mediators of the Natural Defense Against Malignant Tumors	10
<i>G. Mathé, I. Florentin, M. Bruley-Rosset, and N. Kiger:</i> Progress in Experimental Systemic Active Immuno- therapy of Cancer	16
<i>E. Gorelik, S. Segal, and M. Feldman:</i> Host's Immune State and Kinetics of Local Tumor Growth Control – Progression of Postoperative Lung Metastasis	20
<i>P. Reizenstein, C. Ogier, and A.-M. Sjögren:</i> Immunotherapy Versus Chemotherapy of Acute Myeloid Leukemia: Response to PHA, Allogeneic Lymphocytes, and Leukemic Myeloblasts of Remission Lymphocytes from Leukemia Patients	29
<i>R. Huchet, Y. Thomas, and D. Grandjon:</i> Suppressor Cells in Hodgkin's Disease and Lung Carcinoma	37
<i>B. Serrou, L. Gauci, J. Caraux, D. Cupissol, C. Thierry, and C. Esteve:</i> Immune Imbalance in Cancer Patients	41
<i>A. Goutner, F. Nasrat, D. Bonardelle, and G. Rameau:</i> Immunorestitution of Anergic Cancer Patients by Azimexon	47
<i>F. R. Seiler and H.-H. Sedlacek:</i> BCG Versus VCN: The Antigenicity and the Adjuvant Effect of Both Compounds	53

<i>T. Ohnuma, H. Arkin, and J. F. Holland:</i> Differences in Chemotherapeutic Susceptibility of Human T-, B-, and Non-T-/Non-B-Lymphocytes in Culture	61
<i>M. Vierbuchen, P. J. Klein, G. Uhlenbruck, H. O. Klein, H. E. Schaefer, and R. Fischer:</i> The Significance of Lectin Receptors in the Kidney and in Hypernephroma (Renal Adenocarcinoma)	68
<i>C. Rosenfeld, M. C. Martyré, J. L. Pico, B. Serrou, and M. Greaves:</i> Specific Immunotherapy of Acute Lymphoid Leukemia Patients by REH Cell Line	76
<i>E. Robinson, A. Bartal, and T. Mekori:</i> Results of Postoperative Treatment of Colorectal Cancer by Radiotherapy, Chemotherapy and Immunotherapy	80
<i>L. Israel:</i> Some "Pharmacologic" Data About <i>Corynebacterium</i> <i>Parvum</i>	88
<i>L. Dazord, Y. le Garrec, M. Bonnier, and L. Toujas:</i> Increased Resistance to Tumor Graft in Mice Infected by Vaccinal Strains of <i>Brucella Abortus</i>	92
<i>G. D. Marshall, Jr., G. B. Thurman, T. L. K. Low, and A. L. Goldstein:</i> Thymosin: Basic Properties and Clinical Application in the Treatment of Immunodeficiency Diseases and Cancer	100
<i>J.-F. Bach:</i> One or Several Thymic Hormones?	106
<i>B. Serrou, D. Cupissol, J. Caraux, C. Thierry, C. Rosenfeld, and A. L. Goldstein:</i> Ability of Thymosin to Decrease in Vivo and in Vitro Suppressor Cell Activity in Tumor Bearing Mice and Cancer Patients	110
<i>H. Umezawa:</i> Screening of Small Molecular Microbial Products Modulating Immune Responses and Bestatin	115
<i>S. Oka:</i> A Review of Clinical Studies of Bestatin	126
<i>H. Blomgren, L. E. Strender, and F. Edsmyr:</i> Bestatin Treatment and the Peripheral Lymphocyte Population in Cancer Patients	133

<i>M. Bruley-Rosset, I. Florentin, N. Kiger, J. I. Schulz, and G. Mathé:</i> Correction of Immunodeficiency in Aged Mice by Levamisole and Bestatin Administration	139
<i>U. Bicker:</i> Therapeutic Effects of BM 12,531 (Prop. INN Azimexon)	147
<i>I. Florentin, J. Schulz, M. Bruley-Rosset, N. Kiger, T. Martinez, and G. Mathé:</i> In Vivo Immunomodulating Properties of Two Synthetic Agents: Azimexon and Tuftsin	153
<i>J. W. Hadden and R. G. Coffey:</i> Effects of BM 12,531 (Azimexon) on in Vitro Lymphocyte and Macrophage Proliferation	162
<i>N. R. di Luzio, D. L. Williams, R. B. McNamee, and V. G. Malshet:</i> Comparative Evaluation of the Tumor Inhibitory and Antibacterial Activity of Solubilized and Particulate Glucan	165
<i>J. Leibovici, Y. Stark, T. Eldar, G. Brudner, and M. Wolman:</i> Mechanism of the Inhibitory Effect of Levan on Experimental Tumors	173
<i>J. Wybran:</i> Lynestrenol: A Progesterone like Agent with Immunostimulatory Properties	180
<i>A. Goldin, A. Nicolin, and E. Bonmassar:</i> Chemotherapy Immunogenicity	185
<i>M. J. Ehrke, K. Ryoyama, V. Tomazic, S. A. Cohen, and E. Mihich:</i> Selective Imbalances of Cellular Immune Responses by Adriamycin	195
<i>F. Spreafico:</i> The Heterogeneity of the Interaction Between Cancer Chemotherapeutic Agents and Host Resistance Mechanisms	200
<i>H. F. Oettgen, E. A. Carswell, R. L. Kassel, N. Fiore, B. Williamson, M. K. Hoffmann, K. Haranaka, and L. J. Old:</i> Endotoxin-Induced Tumor Necrosis Factor	207
<i>M. Parant:</i> Antimicrobial Resistance Enhancing Activity of Tumor Necrosis Serum Factor Induced by Endotoxin in BCG- Treated Mice	213

<i>N. Kiger, A. Khalil, and G. Mathé:</i> Tumor-Necrotizing Serum Production by Administration of BCG + <i>Pseudomonas</i> : Its Application in Treatment of Fibrosarcoma in Mice . . .	220
<i>I. Gresser:</i> Usefulness of the Results of Studies on the Antitumor Effects of Interferon in Animals to Interferon-Therapy of Patients	226
<i>A. Trouet, R. Baurain, D. Deprez-De Campeneere, D. Layton, and M. Masquelier:</i> DNA, Liposomes, and Proteins as Carriers for Antitumoral Drugs	229
<i>R. Arnon, E. Hurwitz, and M. Sela:</i> Antibodies as Carriers for Oncostatic Materials	236
<i>I. J. Fidler, A. Raz, W. E. Fogler, and G. Poste:</i> Pulmonary Localization of Intravenously Injected Liposomes	246
<i>U. Zimmermann, G. Pilwat, and J. Vienken:</i> Erythrocytes and Lymphocytes as Drug Carrier Systems: Techniques for Entrapment of Drugs in Living Cells	252
<i>F. M. Muggia:</i> Chemo- and Immunopharmacology: The Reality and the Horizons of Cancer Treatment	260